Clinical trials: Residual Disease
Colorectal Cancer, Regorafenib
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy
- Conditions
- Colorectal Cancer, Regorafenib, High Risk Patients
- Trial name
- NCT07071961
- Testing
- Regorafenib (CT), Lorigerlimab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Amblyopia
Combined Patching-Atropine for Residual Amblyopia
This study is designed to evaluate the effectiveness of treatment of residual amblyopia in children ages 3 to < 10 years with visual acuity of 20/32 to 20/63 in the amblyopic eye.
- Trial name
- ATS11 (NCT00506675)
- Testing
- Patching, Atropine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Jaeb Center for Health Research
Breast Cancer
Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer
Breast cancer seriously threatens the health of women worldwide. The HER-2-positive subtype accounts for approximately 15% to 20%, featuring strong invasiveness and poor prognosis.
- Trial name
- NCT07132502
- Testing
- ctDNA MRD
- Volunteers
- 24 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
End Stage Renal Disease
Theranova Versus High-flux Dialyzer on Preservation of Residual Renal Function
Theranova is a novel medium cut-off dialyzer and has better performance for removal of middle molecules compared to conventional hemodialysis.
- Trial name
- THREAD (NCT04211571)
- Testing
- Theranova 400 dialyzer, High-flux dialyzer
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Kyungpook National University Hospital
Stroke
Identifying Personalized Brain States Predicting Residual Corticospinal Tract Output After Stroke
Transcranial magnetic stimulation (TMS) interventions could feasibly strengthen residual corticospinal tract (CST) connections and promote poststroke hand motor recovery.
- Trial name
- NCT06365099
- Testing
- Single-pulse TMS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Texas at Austin
Obesity, Morbid
Residual Gastric Area and Weight Loss After Sleeve Gastrectomy
BACKGROUND: The aim of this study is to evaluate the impact of the actual size and area of the remnant stomach, as measured by Upper gastrointestinal tract radiography, on weight loss after LSG.
- Trial name
- NCT05151107
- Testing
- The radiographic images were collected through a software called "PACS" which combined with a viewer for image processing, that allows the calculation of the residual stomach area (RSA).
- Where
- 2 sites in Italy
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Foggia
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Residual Limb Pain, Amputation Neuroma
Surgical Treatments for Postamputation Pain
This is a double-blind randomised controlled trial (RCT) which compares the effectiveness of three surgical techniques for alleviating residual limb pain (RLP), neuroma pain and phantom limb pain (PLP).
- Conditions
- Residual Limb Pain, Amputation Neuroma, Phantom Limb Pain, Pain, Neuropathic
- Trial name
- NCT05009394
- Testing
- Targeted Muscle Reinnervation (TMR), Regenerative Peripheral Nerve Interface (RPNI), Standard neuroma treatment, neuroma excision, and muscle burying
- Where
- 9 sites in United States, Australia and 5 more
- Volunteers
- 110 people
- Sponsor
- Prometei Pain Rehabilitation Center
Leukemia, Lymphocytic, Acute, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
The clinical study of CART19 Cells treatment for MRD of B Cell Malignancies and then auto-HSCT
- Conditions
- Leukemia, Lymphocytic, Acute, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
- Trial name
- NCT03685786
- Testing
- CART19 cell and auto-HSCT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Second People's Hospital
Lung Cancer (NSCLC)
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT)…
- Trial name
- NCT06771960
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangdong Provincial People's Hospital
Cervical Cancer
The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer
The aim of this trial was to evaluate the efficacy of adjuvant chemotherapy in the locally advanced cervical cancer with residual lesions after concurrent chemoradiation therapy.
- Trial name
- CQGOG0102 (NCT04409860)
- Testing
- CCRT, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chongqing University Cancer Hospital
Schizophrenia
Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia
Amantadine as add-on therapy to antipsychotics may improve schizophrenia positive, negative and cognitive symptoms.
- Trial name
- NCT00999505
- Testing
- Amantadine
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Multiple Myeloma
Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while copy number variation (CNV) is a widely accepted biomarker used for multiple myeloma (MM).
- Trial name
- NCT06302699
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Non Small Cell Lung Cancer
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
The purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery.
- Trial name
- DNA-PREDICT (NCT06902272)
- Testing
- Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Cancer
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90).
- Trial name
- NCT02973399
- Testing
- SNX-5422 plus ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Esanex Inc.
Non-Small Cell Lung Cancer (NSCLC)
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
Neoadjuvant immunotherapy combined with platinum-based doublet chemotherapy has been established as the standard of care for driver-gene-negative (EGFR/ALK wild-type) stage II-IIIB non-small cell lung cancer (NSCLC), yielding…
- Trial name
- NCT07885709
- Testing
- PD-1 inhibitor, Carboplatin, Nab-paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal…
- Trial name
- PNH (NCT05876312)
- Testing
- ADX-038
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ADARx Pharmaceuticals, Inc.
Cervical Cancer
Construction and Validation of a Diagnostic Model for Predicting Molecular Residual Disease and Recurrence of Cervical Cancer Based on Circulating Tumor HPV
Systematic evaluation of the value of molecular residual lesions of cervical cancer based on circulating tumor HPV in the prognostic evaluation and recurrence monitoring of cervical cancer patients.
- Trial name
- NCT06456112
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Anhui Provincial Hospital
Multiple Myeloma
Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients
This study will evaluate the efficacy and safety of 3-drug all-oral combination, ixazomib plus lenalidomide plus dexamethasone (IRd) as induction treatment for autologous stem cell transplantation eligible patients followed by…
- Trial name
- NCT03376672
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 26 sites in Finland, Lithuania and 2 more
- Volunteers
- 120 people
- Sponsor
- Raija Silvennoinen
Head and Neck Cancer
A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment
The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer who have…
- Trial name
- NCT07179315
- Testing
- cemiplimab+fianlimab, Cemiplimab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Chicago